Effectiveness And Safety Of Baricitinib In Alopecia Areata: A Prospective Cohort Study

This prospective cohort study evaluated the real-world effectiveness and safety of Baricitinib in 48 adults with severe alopecia areata over a 12-month period. The study found that Baricitinib is effective and safe for managing severe AA, with the primary endpoint being a SALT score of less than 20% sustained over two consecutive assessments. Favorable responses were associated with lower baseline SALT scores, shorter disease duration, and higher basal erythrocyte sedimentation rates. No serious adverse events were reported, emphasizing the importance of early intervention and appropriate patient selection for optimal outcomes.